JP2009534339A5 - - Google Patents

Download PDF

Info

Publication number
JP2009534339A5
JP2009534339A5 JP2009505780A JP2009505780A JP2009534339A5 JP 2009534339 A5 JP2009534339 A5 JP 2009534339A5 JP 2009505780 A JP2009505780 A JP 2009505780A JP 2009505780 A JP2009505780 A JP 2009505780A JP 2009534339 A5 JP2009534339 A5 JP 2009534339A5
Authority
JP
Japan
Prior art keywords
amino
purin
propionylamino
cyclopentane
ethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534339A (ja
Filing date
Publication date
Priority claimed from GBGB0607953.7A external-priority patent/GB0607953D0/en
Application filed filed Critical
Publication of JP2009534339A publication Critical patent/JP2009534339A/ja
Publication of JP2009534339A5 publication Critical patent/JP2009534339A5/ja
Pending legal-status Critical Current

Links

JP2009505780A 2006-04-21 2007-04-19 アデノシンa2a受容体アゴニストとして使用するためのプリン誘導体 Pending JP2009534339A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607953.7A GB0607953D0 (en) 2006-04-21 2006-04-21 Organic compounds
PCT/EP2007/003436 WO2007121921A2 (en) 2006-04-21 2007-04-19 Purine derivatives for use as adenosin a2a receptor agonists

Publications (2)

Publication Number Publication Date
JP2009534339A JP2009534339A (ja) 2009-09-24
JP2009534339A5 true JP2009534339A5 (cg-RX-API-DMAC10.html) 2011-06-23

Family

ID=36581050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505780A Pending JP2009534339A (ja) 2006-04-21 2007-04-19 アデノシンa2a受容体アゴニストとして使用するためのプリン誘導体

Country Status (12)

Country Link
US (1) US20090105476A1 (cg-RX-API-DMAC10.html)
EP (1) EP2012760A2 (cg-RX-API-DMAC10.html)
JP (1) JP2009534339A (cg-RX-API-DMAC10.html)
KR (1) KR20080110923A (cg-RX-API-DMAC10.html)
CN (1) CN101426483A (cg-RX-API-DMAC10.html)
AU (1) AU2007241344A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0710655A2 (cg-RX-API-DMAC10.html)
CA (1) CA2648813A1 (cg-RX-API-DMAC10.html)
GB (1) GB0607953D0 (cg-RX-API-DMAC10.html)
MX (1) MX2008013418A (cg-RX-API-DMAC10.html)
RU (1) RU2008145701A (cg-RX-API-DMAC10.html)
WO (1) WO2007121921A2 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20100068286A (ko) * 2007-10-17 2010-06-22 노파르티스 아게 아데노신 a1 수용체 리간드로서의 퓨린 유도체
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
US9394310B2 (en) 2010-12-03 2016-07-19 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
CN103391939B (zh) 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
WO2014152566A2 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
JP2000502709A (ja) * 1996-01-02 2000-03-07 ローヌ―プーラン ローラー ファーマシューティカルズ インコーポレイテッド 2,4―ジヒドロキシピリジン及び2,4―ジヒドロキシ―3―ニトロピリジンの製造方法
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9813535D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1383427A (zh) * 1998-12-31 2002-12-04 阿温蒂斯药物公司 制备n6-取代的脱氮杂一腺苷衍生物的方法
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
CA2434906C (en) * 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1699459B1 (en) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
KR20070004792A (ko) * 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
KR20070050484A (ko) * 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 A1 및 a3 아데노신 수용체 아고니스트로서의 퓨린 유도체
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2006084281A1 (en) * 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
JP5339916B2 (ja) * 2005-11-30 2013-11-13 キャン−ファイト・バイオファーマ・リミテッド 骨関節炎の治療におけるa3アデノシン受容体アゴニストの使用
DK1983990T3 (da) * 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds

Similar Documents

Publication Publication Date Title
CN101062932A (zh) 制备10,11-二氢-10-羟基-5H-二苯并[b,f]氮杂䓬-5-甲酰胺的对映选择性方法及其新晶形
JP2007523213A (ja) 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
CN100343227C (zh) 坦洛新的拆分方法
Wang et al. L-Pipecolinic acid derived Lewis base organocatalyst for asymmetric reduction of N-aryl imines by trichlorosilane: Effects of the side amide group on catalytic performances
CN1882535A (zh) 2-氧代-1-吡咯烷衍生物的制备方法
CN1602305A (zh) 异西酞普兰的制备方法
CN102964323A (zh) 一种5-(哌嗪-1-基)苯并呋喃-2-甲酰胺的合成方法
Sato et al. Highly enantioselective asymmetric autocatalysis of 2‐alkenyl‐and 2‐vinyl‐5‐pyrimidyl alkanols with significant amplification of enantiomeric excess
JP2008519023A5 (cg-RX-API-DMAC10.html)
JP2009062360A (ja) シナカルセットの製造方法
CN103304447B (zh) (s)-卡巴拉汀的合成工艺
JP4170990B2 (ja) 光学的に活性であるセリン誘導体の製造方法
US20100249438A1 (en) Preparation of escitalopram
CN103254107A (zh) 一种依泽替米贝类似物及其制备方法
Zhao et al. Concise and diastereoselective approach to syn-and anti-N-tosyl-α-hydroxy β-amino acid derivatives
CN1777586A (zh) 稳定的无定形樟脑磺酸氨氯地平、其制备工艺以及其口服给药的组合物
WO2014139410A1 (zh) 一种阿折地平中间体的制备方法
WO1999046252A1 (en) Process for producing oxazolidin-2-one derivatives
WO2011070585A1 (en) Processes for preparing rivastigmine, salts and intermediates thereof
US20110230666A1 (en) process for the separation of enantiomerically pure compounds
CN1309708C (zh) 酶化学法合成光学活性氰醇化合物
JP2009215195A (ja) 5’−フルオロサリドマイド誘導体及びその製造方法
WO2008124969A1 (en) Preparation method of rivastigmine and its intermediates
WO2004011451A1 (ja) 光学活性1,4−ベンゾジオキサン誘導体の工業的製法
WO2011160396A1 (zh) 一种雷诺嗪的制备方法